Oramed Pharmaceuticals (ORMP) Expected to Announce Earnings on Wednesday

Key Points

• Oramed Pharmaceuticals (NASDAQ:ORMP) is set to release its earnings on August 13th, with analysts predicting a loss of ($0.01) per share for the quarter.
• In its previous earnings report, Oramed missed expectations, reporting a loss of ($0.19) EPS and generating $2.00 million in revenue.
• Jane Street Group LLC increased its stake in Oramed by 35.3%, now holding approximately 0.16% of the company, indicating growing institutional interest.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect Oramed Pharmaceuticals to post earnings of ($0.01) per share for the quarter.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.16). The firm had revenue of $2.00 million for the quarter. On average, analysts expect Oramed Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oramed Pharmaceuticals Stock Performance

Oramed Pharmaceuticals stock traded up $0.01 during trading hours on Friday, hitting $2.09. The company had a trading volume of 36,346 shares, compared to its average volume of 69,867. The firm has a market cap of $85.38 million, a P/E ratio of -4.75 and a beta of 1.60. The company has a 50-day moving average price of $2.16 and a two-hundred day moving average price of $2.22. Oramed Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $3.09.

Institutional Investors Weigh In On Oramed Pharmaceuticals

An institutional investor recently raised its position in Oramed Pharmaceuticals stock. Jane Street Group LLC raised its holdings in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 35.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 67,173 shares of the biotechnology company's stock after purchasing an additional 17,510 shares during the period. Jane Street Group LLC owned 0.16% of Oramed Pharmaceuticals worth $144,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.73% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, May 17th.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.